Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
about
Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infectionTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensPhotodynamic therapy using systemic administration of 5-aminolevulinic acid and a 410-nm wavelength light-emitting diode for methicillin-resistant Staphylococcus aureus-infected ulcers in mice.Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.Telavancin: a new lipoglycopeptide with multiple mechanisms of action.The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureusTelavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in miceEfficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection modelCombinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infectionIntrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.Telavancin: a novel lipoglycopeptide for serious gram-positive infections.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).Telavancin: a novel lipoglycopeptide antibiotic.A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.Telavancin: a review of its use in patients with nosocomial pneumonia.Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infectionPharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic modelSuccessful target attainment of telavancin at elevated MICs: fact or fiction?An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic.Affect of linezolid in ventilator-associated pneumonia caused by MRSA.Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.Reply to “Successful Target Attainment of Telavancin at Elevated MICs: Fact or Fiction?”.Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.
P2860
Q33622963-F434CAB7-8C62-4C0A-B805-CC0A06D2F72CQ33788308-130EFE04-40DA-4EA7-82F9-63EBFFBF4FF1Q34070740-EEFA210A-F5B3-4705-A4B0-BD86A0858A05Q34309620-0864636D-37D4-4999-AA71-AF8C2447932BQ34572923-C991E133-4E35-4663-AB64-F72AA58BCBBCQ34672655-E5EC1989-679D-4FA9-B90A-5EEBED9E8418Q35879100-96F76ACA-9378-43C5-932F-C9CE0CCF37DEQ35905561-3F9EF058-2055-4F0D-A57D-A1F36A46062DQ35941476-24AC64ED-C3DA-4B1D-B790-DB51DAE7058FQ36018587-30CA753E-1A96-4E57-8F2D-711A5F9EF6AAQ36292752-71E9DE7C-8E40-44C2-97A7-30146C165941Q36422696-15A22323-5C82-44CF-8799-5E4205BC2642Q36736356-B474C240-94F9-4A75-819E-69A5C584C8F0Q36777850-1E59AB28-8F2C-4554-9C82-7255C0337FC5Q37077627-EE1E7B92-7F6C-41EB-9CDF-84AA2AA8DA60Q37117865-CEE3508B-77FC-4F13-B0B5-225D5ED8EF18Q37252733-D9937D57-9AE4-4B80-880F-CF13F95E13B3Q37463589-B19D793D-1826-41CC-8627-DF1BEAEEF8FBQ37661510-9A8E2D1A-C089-4A72-BA88-8F7B62F64867Q37955286-E80FABC5-E09A-436B-BEAE-6BF31AA271E1Q38048845-42A5AFEE-134C-48E3-ADEE-DE335AD304ADQ38159966-17DC66D5-8C7F-431B-999F-D344F2D645BEQ38266421-BAB440D3-4C23-498C-B9B5-7AB29CD7CE6AQ38522574-14361833-9E7C-46CE-87C0-CCDC03E69FCEQ38530316-BDB2A59A-593A-4EB9-9F15-36B29705BE40Q38627072-D3ED6455-43C0-470A-8C24-F912E7E4275CQ38646905-0D4218AA-2E11-4AA9-B58F-B6AA6D308545Q39267105-D7524ED3-BD47-44E7-9DA5-41D1145782E5Q41884344-20C1E08F-7866-4D70-A874-994BC99B9BECQ41925060-850329C7-7F38-4BA7-9F55-B3D9CC135C24Q42627265-868D4810-09C9-4E79-BE94-049596FE716EQ43243482-F1094A74-A611-4FD0-9F9F-55E6C306187AQ43845142-5A87D7B7-316C-4085-8497-6A62EBC03433Q46103421-F6F917AF-F035-498C-8BD9-C389D0B4A27DQ46489824-D863FE3A-269A-46AC-BD26-4048430DFF52Q46679956-5D4FC112-880E-49AE-A012-3E5A28A27C4CQ47236751-CCAEBF40-52D8-405A-8CAC-F14E3BEDB2D6
P2860
Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@ast
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@en
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@nl
type
label
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@ast
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@en
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@nl
prefLabel
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@ast
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@en
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@nl
P2093
P2860
P1476
Efficacy of telavancin (TD-642 ...... sistant Staphylococcus aureus.
@en
P2093
Alexander Gough
Glenmar P Obedencio
Josephine Shelton
Kevin M Krause
Koné Kaniga
Michael Conner
Robert Skinner
Sharath S Hegde
P2860
P304
P356
10.1128/AAC.49.10.4344-4346.2005
P407
P577
2005-10-01T00:00:00Z